Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations
Alecia Blaszczak, John Trinidad, Alexander M. Cartron
Topics & Concepts
MedicineHidradenitis suppurativaAdalimumabPandemicCoronavirus disease 2019 (COVID-19)Psoriasis2019-20 coronavirus outbreakDermatologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)DiseaseCoronavirusIntensive care medicineInternal medicineVirologyInfectious disease (medical specialty)OutbreakHidradenitis Suppurativa and TreatmentsMicroscopic ColitisChemotherapy-related skin toxicity